Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Athyrium Capital Management, LP

Q2 2024 · 13F-HR

Athyrium Capital Management, LPholdings as filed

Filed 2024-08-08 · accession 0001123292-24-000213

$33.5M
Reported value
3
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
19249HAB9COHERUS BIOSCIENCES INC$22.2M66.3%30,000,000CommonNONE
74319F305Biora Therapeutics Inc.$7.2M21.5%10,929,762CommonSOLE
74587V107PBYIPUMA BIOTECHNOLOGY INC$4.1M12.2%1,256,411CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.